Search - tctmd.com

Displaying 121 - 140 of 616

Sort: Relevancy | Date

News Daily News

NIH Presses Pause on Cardiac Stem Cell Trial, Further Muddying a Murky Field

Shelley Wood

November 02, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Michael O'Riordan

July 20, 2018

News Daily News

Discharge Against Medical Advice After PCI Rare but Deadly

Michael O'Riordan

July 17, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Industry News

BioCardia Receives New Potency Assay Patent, Providing Further Protection to Autologous Cell Therapy Programs in Heart Failure and Refractory Angina

April 25, 2018

News Conference News ACC 2018

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

Shelley Wood

March 27, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Yael L. Maxwell

March 11, 2018

News Conference News ISET 2018

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

Caitlin E. Cox

February 05, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Daily News

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

Todd Neale

December 04, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shelley Wood

November 09, 2017

$My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!$

Presentation TCT 2017

My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!

Presenter: Timothy D. Henry, Marc S. Penn

October 31, 2017

Presentation TCT 2017

In Which Direction is Cell Based Heart Failure Therapy Headed?

Presenter: Francisco Fdez-Aviles, Emerson C. Perin

October 31, 2017

Presentation TCT 2017

The Clinical Point of View: Is There an AMI Need for Cell Therapy?

Presenter: Francisco Fdez-Aviles, Ricardo Sanz-Ruiz, Jose M. de la Torre Hernandez

October 31, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Photosynthetic Bacteria May Aid in Repair of Myocardial Ischemia

L.A. McKeown

June 14, 2017

Advertisement

NIH Presses Pause on Cardiac Stem Cell Trial, Further Muddying a Murky Field

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Discharge Against Medical Advice After PCI Rare but Deadly

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

BioCardia Receives New Potency Assay Patent, Providing Further Protection to Autologous Cell Therapy Programs in Heart Failure and Refractory Angina

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!

In Which Direction is Cell Based Heart Failure Therapy Headed?

The Clinical Point of View: Is There an AMI Need for Cell Therapy?

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Photosynthetic Bacteria May Aid in Repair of Myocardial Ischemia

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content